Product Description
Nonprescription fluticasone nasal spray (Flonase Allergy) is used to relieve symptoms of rhinitis such as sneezing and a runny, stuffy, or itchy nose and itchy, watery eyes caused by hay fever or other allergies (caused by an allergy to pollen, mold, dust, or pets). Prescription fluticasone is also used to relieve symptoms of nonallergic rhinitis such as sneezing and runny or stuffy nose which are not caused by allergies.
Mechanisms of Action: LAB Agonist,Corticosteroid Hormone Receptor Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical,Inhalant,Nasal
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Rhinitis | Rhinitis, Allergic | Rhinitis, Allergic, Perennial | Spasm | Asthma | Spasm | Asthma | Nasal Polyposis | Chickenpox | Measles | Spasm | Asthma | Spasm | Asthma
Known Adverse Events: Headache | Pharyngitis | Epistaxis | Nasopharyngitis | Respiratory Tract Infections | Bronchitis | Candidiasis | Erythema | Sinusitis | Candidiasis, Oral | Inflammation | Rhinitis | Back Pain | Pain Unspecified
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Brazil, Bulgaria, Canada, China, Czech Republic, Denmark, Georgia, Germany, Greece, Hungary, India, Italy, Japan, Latvia, Mexico, New Zealand, Poland, Romania, Russia, Slovakia, South Africa, Spain, Sweden, United Kingdom, United States
Active Clinical Trial Count: 28
Highest Development Phases
Phase 3: Asthma|Chronic Cough|Chronic Obstructive Pulmonary Disease|Inflammation|Nasal Polyposis|Respiratory Aspiration|Rhinitis, Allergic, Perennial|Sinusitis
Phase 1: Rhinitis, Allergic, Seasonal
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TRIPLAR | P3 |
Not yet recruiting |
Chronic Obstructive Pulmonary Disease |
2027-11-30 |
|
| FpA-AS-30094 | P3 |
Unknown Status |
Asthma |
2026-12-31 |
|
| FORASMA | P3 |
Not yet recruiting |
Asthma |
2026-05-30 |
78% |
| FORASMA | P3 |
Not yet recruiting |
Asthma |
2026-05-30 |
78% |
| FpA-AS-30093 | P3 |
Not yet recruiting |
Asthma |
2026-05-11 |